Deepbridge Life Sciences EIS

NB: Due to a significant change in the application process for Advanced Assurance that has been introduced by HMRC which will affect the whole market, it is not possible to commit to investing the SEIS portfolio, being closed on the 24th of March in this current tax year, for carry back purposes. Due to our current book of existing EIS and SEIS companies we believe that we can invest our EIS in this tax year for carry back purposes. If you have any questions or seek clarification please contact Piers Denne on 07837715679

Investment Objective

Providing investment to emerging companies operating in the life sciences sector, the Deepbridge Life Sciences EIS seeks to finance companies with exciting new technologies that satisfy the needs of large and growing markets. The investment strategy of the Deepbridge Life Sciences EIS is to invest in a diversified portfolio of up to ten investee companies that participate in one of the following:

  • Biopharmaceuticals
  • Biotechnology
  • Medical Technology

The Deepbridge Life Sciences Team seeks to invest in companies that possess some or all of the following attributes:

  • A focus on life sciences and medical device technology
  • Significant market potential with clear need and market growth
  • Provide a solution to a recognised clinical or healthcare need
  • Innovation-driven products that have the potential to create new market segments or displace current technologies
  • Medical technology businesses with a clear and realistic path to commercialisation
  • Robust intellectual property which may provide patented or patentable IP protection
  • Passionate, energetic, experienced and aligned founding team
  • Clear exit strategy to be implemented within 4-5 years with alignment of interests with our stakeholders

Please note that not all attributes may be achievable in each investment.

Exit Strategy

The Deepbridge team believes that most exits in the technology sector will take place in the M&A space, and so aim to execute business models suitable for this exit route. The Deepbridge team will assess any opportunity to capitalise on exit opportunities, notwithstanding the 3 year EIS period, if an early exit is in Investors’ best interests. Deepbridge believes that either a sale of the Investee Companies, or a sale or refinancing of the assets owned by the Investee Companies, will enable funds to be returned to Investors.

Fund Manager

Enterprise Investment Partners LLP

Enterprise Investment Partners LLP is a specialist smallcap investment boutique established over five years ago, whose activities include corporate finance, fund management and the design and promotion of tax-efficient investment products, with major emphasis on EIS. Enterprise has considerable experience of EIS and the tax-efficient industry, with particular expertise in the leisure, media, commercial property and renewable energy sectors. The three principals together have raised over £200m under EIS, VCT and other tax efficient structures over the last five years.

For more information please visit enterprise-ip.com

Fund Provider

Deepbridge Advisers Limited

Deepbridge is a different kind of investment manager. We work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. We also partner with innovative and committed management teams to help UK based companies realise their potential and become successful leading-edge businesses. Deepbridge operates across four principle divisions: disruptive technology, sustainable technologies, life sciences and renewable energy.

Successful investment in growing companies requires an appropriate balance between entrepreneurial optimism and venture capital realism. Investors can be blinded by the potential upside; however, seeing the path to commercialisation from a realistic standpoint demands an objective and experienced perspective from the Investment Manager.

Fees

Corporate Advisory and Arrangement Costs

Paid by the Investee Company: up to 5% of funds invested in that company

Annual Maintenance Fee

Paid by the Investee Company: 2% p.a.

Dealing and Custody Fees

Paid by the Investee Company: The Investment Adviser will charge each Investee Company a dealing fee of 0.65% on the sale and purchase of shares, and a Custody Administration fee of 0.50% p.a. for the provision of custody services.

Performance Incentive Fee

An incentive fee of 20% of the amount of cumulative cash returned, in excess of the amount of funds invested in the Investee Companies.

Investor Marketing and Other Fees

The Manager reserves the right to levy additional fees to the Investee Company to meet any costs relating to investor marketing, additional fundraising and administration, custody and services provided.

Shares, Options & Warrants

The Manager may also seek to take shares, options or warrants in the Investee Companies either in lieu of any of the above charges or fees in addition and in line with standard industry practice.

All fees are stated excluding any VAT which may also be charged where applicable.

Kuber Specific Arrangements

Kuber receives a fundraising fee of 1.0% from the manager. Kuber will return this fee to Investors by applying it to their Subscription amount thereby increasing their investment.

For further information please do not hesitate to

contact us on:

+44 (0) 20 7952 6685
info@kuber.uk.com
www.kuberventures.co.uk

Fund at a glance

Scheme Categorisation

The Scheme is structured as an Discretionary managed portfolio service

Target Return

170p for every 100p invested, over a minimum 4-year period, an equivalent return of c.22.4% per annum.

Scheme Strategy

Private equity

Investment Sector

Life Sciences

Target Diversification

Up to ten investee companies targeted per investor to the portfolio

Nominee & Custody Arrangements

The Nominee: Woodside Nominees Limited

The Custodian: Woodside